Virtus Biotech Clinical Trials ETF
10 hedge funds and large institutions have $8.57M invested in Virtus Biotech Clinical Trials ETF in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
150% more funds holding
Funds holding: 4 → 10 (+6)
11% more capital invested
Capital invested by funds: $7.75M → $8.57M (+$825K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.11M |
| 2 |
LPL Financial
San Diego,
California
|
+$581K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$436K |
| 4 |
BAAM
Baker Avenue Asset Management
San Francisco,
California
|
+$248K |
| 5 |
Jane Street
New York
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.23M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$1.16M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| $6.57M | +$6.11M | +200,000 | New |
|
|
2
LPL Financial
San Diego,
California
| $624K | +$581K | +19,020 | New |
|
|
3
Jane Street
New York
| $565K | +$136K | +4,459 | +35% |
|
|
CS
4
Credit Suisse
Zurich,
Switzerland
| $469K | +$436K | +14,272 | New |
|
|
BAAM
5
Baker Avenue Asset Management
San Francisco,
California
| $267K | +$248K | +8,120 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $52K | +$47K | +1,540 | +5,133% |
|
|
MPWT
7
MassMutual Private Wealth & Trust
Windsor,
Connecticut
| $8.14K | +$7.58K | +248 | New |
|
8
UBS Group
Zurich,
Switzerland
| $8K | +$7.15K | +234 | New |
|
9
Creative Planning
Overland Park,
Kansas
| $7K | +$6.11K | +200 | New |
|
10
Morgan Stanley
New York
| $5K | +$5.19K | +170 | New |
|
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$6.23M | -224,754 | Closed |
|
|
VKH
12
Virtu KCG Holdings
New York
| – | -$1.16M | -41,727 | Closed |
|
BBC Hedge Fund Activity: Q1 2015 in Review
10 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2015, worth a combined $8.57M — up 11% from $7.75M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BBC positions and 2 closed out — a net gain of 6 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $6.11M. The largest seller was Deutsche Bank, exiting entirely with an estimated $6.23M sold.
- 10 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2015, up from 4 in Q4 2014.
- Funds reported $8.57M of Virtus Biotech Clinical Trials ETF stock for Q1 2015, up 11% quarter-over-quarter.
- 8 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2015 and 2 closed out, a net change of +6 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2015 was Goldman Sachs, an estimated $6.11M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2015 was Deutsche Bank, an estimated $6.23M sold.
Based on aggregated 13F filings for Q1 2015.